Intermediateapplied biology
Insulin: From Dog Pancreases to Recombinant DNA
Learning objectives
- Narrate the 1921 discovery of insulin in Toronto.
- Explain the limitations of animal-extracted insulin.
- Describe how recombinant DNA produces human insulin in bacteria.
- Evaluate insulin as the founding product of biotechnology.
Background: The Discovery That Saved Millions
Before 1921, a diagnosis of type 1 diabetes was a death sentence. Without insulin, the body cannot move glucose from blood into cells; patients — often children — wasted away over months despite eating ravenously, dying in diabetic coma. The pancreas was suspected as the source of the missing factor, but pancreatic extracts were toxic and inconsistent. In 1921, in a cramped Toronto laboratory, surgeon Frederick Banting and medical student Charles Best, working under physiologist J.J.R. Macleod, tied off the pancreatic ducts of dogs to isolate the insulin-producing islet cells, then extracted a preparation that lowered blood sugar. Biochemist James Collip purified the extract to a form safe for humans. In January 1922, 14-year-old Leonard Thompson, dying of diabetes in a Toronto hospital, received the first injection — and lived. The news electrified the world; Banting and Macleod received the 1923 Nobel Prize. Insulin turned a fatal disease into a manageable one within a year of its discovery.
Insulin's story has two revolutions: the 1921 discovery that made diabetes survivable, and the recombinant DNA method that made the treatment abundant.
What Happened: From Slaughterhouse to Fermentation Tank
For six decades, insulin came from animals — primarily the pancreases of pigs and cattle collected at slaughterhouses. It worked, and millions lived because of it, but the supply chain was limiting: it took thousands of animal pancreases to treat a single patient for a year, purification was imperfect, and the slight molecular differences between animal and human insulin caused allergic reactions and variable responses in some patients. The recombinant DNA revolution offered a radical alternative. In the 1970s, scientists learned to cut and paste DNA: the human insulin gene could be inserted into a bacterial plasmid, and the bacterium Escherichia coli — transformed with this recombinant DNA — would transcribe and translate the human gene, manufacturing genuine human insulin protein. Genentech produced recombinant human insulin in 1978, and Eli Lilly brought it to market as Humulin, approved in 1982 — the first drug made by recombinant DNA technology. Bacteria in fermentation tanks replaced slaughterhouses as the source.
The Biological Mechanism: Brewing a Human Protein in Bacteria
The mechanism is applied molecular biology from gene to protein. The human insulin gene — actually two short genes encoding the A and B chains of the insulin molecule — is inserted into plasmid vectors, sometimes as a fused construct later cleaved into the two chains. Transformed E. coli, grown in massive fermenters, express the genes using their own transcription and translation machinery; the universality of the genetic code means bacterial ribosomes correctly read human codons. The protein is harvested, purified through chromatography, and the A and B chains are joined by the disulfide bonds that give insulin its active structure. Later refinements moved production into yeast, which handles protein folding and secretion more gracefully. The result is molecularly human insulin — identical in amino acid sequence to what the pancreas makes — produced at scales and purities animal extraction could never match, with no risk of animal-derived contaminants.
Outcome and Lessons: The First Biotech Drug
Recombinant insulin did more than improve diabetes care; it proved the entire premise of biotechnology. Humulin showed that engineered microbes could manufacture human therapeutic proteins safely and at scale, opening the door to growth hormone, clotting factors, erythropoietin, monoclonal antibodies, and the modern biopharmaceutical industry — a sector now worth hundreds of billions. It also established the regulatory and social template for genetic engineering in medicine: rigorous purification standards, clinical trials of recombinant products, and public acceptance of a drug made by genetically modified organisms, which faced little of the controversy that later surrounded GM crops. For students, insulin connects every level of biology: the physiology of glucose regulation, the biochemistry of a peptide hormone, the molecular biology of recombinant DNA, and the bioethics of who accesses a life-saving drug — because insulin's price and availability remain contested a century after its discovery.
Exam Angle: Two Revolutions in One Story
Insulin questions reward answers that cover both revolutions. For 1921, name the Toronto team and their roles — Banting and Best (extraction), Collip (purification), Macleod (direction) — and the first patient, Leonard Thompson, in 1922. For the recombinant era, explain the method stepwise: human insulin gene into plasmid, plasmid into E. coli, bacterial expression, purification, chain assembly. Emphasize why it mattered: unlimited supply, human sequence (fewer allergies), and high purity. If asked about biotechnology generally, present Humulin (1982) as the proof-of-concept first recombinant drug. The universality of the genetic code is the key concept that makes the whole method possible — bacteria can read human genes.
The genetic code is universal: the same codons specify the same amino acids in bacteria and humans. That is why E. coli can manufacture a human protein.
Key points
- In 1921, Banting, Best, Collip, and Macleod isolated insulin in Toronto; the first patient was treated in 1922.
- Animal-extracted insulin saved lives but was scarce and sometimes caused allergic reactions.
- Recombinant DNA technology inserted human insulin genes into E. coli bacteria.
- Humulin, approved in 1982, was the first recombinant DNA drug — genuine human insulin at scale.
- Insulin became the proof that biotechnology could manufacture human proteins.
Common misconceptions
✓ Truth: It was a team effort in Toronto — Banting and Best did the lab work, Collip purified the extract, Macleod directed the lab — and it built on decades of prior pancreas research.
✓ Truth: It has the human amino acid sequence, produced by living cells. Recombinant describes the DNA method, not the protein, which is genuine human insulin.
✓ Truth: Type 1 diabetes was a death sentence before insulin — children wasted away within months. Insulin did not just treat the disease; it transformed it from fatal to manageable.
Frequently asked questions
How was diabetes treated before recombinant insulin?
Before recombinant insulin, diabetes was treated with insulin extracted from the pancreases of pigs and cattle. It worked but supply was limited, purification was difficult, and some patients developed allergies to the animal protein.
How do bacteria make human insulin?
Recombinant DNA technology joins a human gene to bacterial DNA. Bacteria carrying the insulin genes transcribe and translate them, producing human insulin protein that is then purified.
When was recombinant insulin approved?
In 1982, Humulin — human insulin made by genetically engineered bacteria — was approved, becoming the first recombinant DNA drug on the market.
Is recombinant insulin identical to human insulin?
They are very close but not identical in every detail of production; analog insulins are modified versions engineered for faster or slower action. Recombinant human insulin matches the human amino acid sequence.